Viatris, Inc. (VTRS)

Viatris's stock price has been significantly impacted by positive earnings reports and strategic updates, surging by 61% over the last six months and 94% over the past year. In Q1 2026, Viatris reported adjusted EPS of $0.59 and revenue of $3.52 billion, exceeding forecasts. The company released its Q4 2025 earnings, reporting an EPS of -0.300 USD. Viatris outlined its strategic vision and long-term financial targets through 2030 at an investor event. An annual general meeting was held on December 5, 2025.

Viatris's products and services exhibit normal product seasonality, with total revenues, adjusted EBITDA, and adjusted EPS expected to be weighted towards the second half of the year, accounting for approximately 52% of its full-year outlook. This seasonality is also influenced by the timing of new product launches. Operating expenses and free cash flow are also expected to be higher in the second half of the year due to working capital timing and one-time operating cash costs.

Viatris Inc. is a global healthcare and pharmaceutical corporation formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn business. The company operates within the Pharmaceuticals and Healthcare sector with a diversified business model encompassing branded, generic, and biosimilar medicines, as well as active pharmaceutical ingredients (APIs). Its product range covers numerous therapeutic areas, including cardiovascular, infectious disease, oncology, and women's healthcare, with major products like Lipitor, Norvasc, and Viagra. Viatris also produces complex generics like Breyna and innovative products like Tyrvaya and Ryzumvi, while focusing on expanding access to essential medicines.

Viatris has a substantial global operating footprint, serving approximately 1 billion patients annually across more than 165 countries and territories. The company's operations are segmented into four key geographic areas: Developed Markets (North America and Europe), Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets (over 125 countries across Asia, Africa, Eastern Europe, Latin America, and the Middle East, including its ARV franchise). Viatris operates a global network of approximately 27 to 40 manufacturing sites across six continents.

Viatris inherited a corporate reputation that had been negatively impacted by pricing controversies from its predecessor company Mylan. Since its formation, Viatris has aimed to build a reputation based on expanding access to medicines, meeting patient needs through innovation, and fostering trust within the healthcare community. The company emphasizes its commitment to sustainability and responsible business practices to strengthen healthcare infrastructure and improve patient outcomes globally. Viatris has focused on strategic divestitures of lower-margin segments to streamline its portfolio and concentrate on higher-value pillars.

Viatris Inc. is primarily owned by institutional investors, who collectively hold a significant majority of the company's shares, accounting for approximately 79.88% to 83.14% of outstanding shares. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and T. Rowe Price Group, Inc. Insider ownership, representing shares held by company executives and directors, is relatively small, standing at around 0.28% to 0.51%.